Switch theme
Sign up to access all valuation multiples
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
2015
227
LTM Revenue $1.6M
LTM EBITDA -$205M
-$130M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
4D Molecular Therapeutics has a last 12-month revenue (LTM) of $1.6M and a last 12-month EBITDA of -$205M.
In the most recent fiscal year, 4D Molecular Therapeutics achieved revenue of $37K and an EBITDA of -$181M.
4D Molecular Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 4D Molecular Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.6M | XXX | $37K | XXX | XXX | XXX |
| Gross Profit | $1.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$205M | XXX | -$181M | XXX | XXX | XXX |
| EBITDA Margin | -12612% | XXX | -489557% | XXX | XXX | XXX |
| EBIT | -$201M | XXX | -$188M | XXX | XXX | XXX |
| EBIT Margin | -12374% | XXX | -507678% | XXX | XXX | XXX |
| Net Profit | -$178M | XXX | -$161M | XXX | XXX | XXX |
| Net Margin | -10979% | XXX | -434778% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, 4D Molecular Therapeutics's stock price is $4.
4D Molecular Therapeutics has current market cap of $168M, and EV of -$130M.
See 4D Molecular Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$130M | $168M | XXX | XXX | XXX | XXX | $-3.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, 4D Molecular Therapeutics has market cap of $168M and EV of -$130M.
4D Molecular Therapeutics's trades at -3510.5x EV/Revenue multiple, and 0.7x EV/EBITDA.
Equity research analysts estimate 4D Molecular Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
4D Molecular Therapeutics has a P/E ratio of -0.9x.
See valuation multiples for 4D Molecular Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $168M | XXX | $168M | XXX | XXX | XXX |
| EV (current) | -$130M | XXX | -$130M | XXX | XXX | XXX |
| EV/Revenue | -80.0x | XXX | -3510.5x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBIT | 0.6x | XXX | 0.7x | XXX | XXX | XXX |
| EV/Gross Profit | -80.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -1.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trial4D Molecular Therapeutics's last 12 month revenue growth is 135%
4D Molecular Therapeutics's revenue per employee in the last FY averaged $0K, while opex per employee averaged $0.8M for the same period.
4D Molecular Therapeutics's rule of 40 is -382% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
4D Molecular Therapeutics's rule of X is -12275% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for 4D Molecular Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 135% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -12612% | XXX | -489557% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 48% | XXX | XXX | XXX |
| Rule of 40 | -382% | XXX | -489422% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -12275% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 381889% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 507778% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
4D Molecular Therapeutics acquired XXX companies to date.
Last acquisition by 4D Molecular Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . 4D Molecular Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was 4D Molecular Therapeutics founded? | 4D Molecular Therapeutics was founded in 2015. |
| Where is 4D Molecular Therapeutics headquartered? | 4D Molecular Therapeutics is headquartered in United States of America. |
| How many employees does 4D Molecular Therapeutics have? | As of today, 4D Molecular Therapeutics has 227 employees. |
| Who is the CEO of 4D Molecular Therapeutics? | 4D Molecular Therapeutics's CEO is Mr. David Kirn, M.D.. |
| Is 4D Molecular Therapeutics publicy listed? | Yes, 4D Molecular Therapeutics is a public company listed on NAS. |
| What is the stock symbol of 4D Molecular Therapeutics? | 4D Molecular Therapeutics trades under FDMT ticker. |
| When did 4D Molecular Therapeutics go public? | 4D Molecular Therapeutics went public in 2020. |
| Who are competitors of 4D Molecular Therapeutics? | Similar companies to 4D Molecular Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of 4D Molecular Therapeutics? | 4D Molecular Therapeutics's current market cap is $168M |
| What is the current revenue of 4D Molecular Therapeutics? | 4D Molecular Therapeutics's last 12 months revenue is $1.6M. |
| What is the current revenue growth of 4D Molecular Therapeutics? | 4D Molecular Therapeutics revenue growth (NTM/LTM) is 135%. |
| What is the current EV/Revenue multiple of 4D Molecular Therapeutics? | Current revenue multiple of 4D Molecular Therapeutics is -80.0x. |
| Is 4D Molecular Therapeutics profitable? | Yes, 4D Molecular Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of 4D Molecular Therapeutics? | 4D Molecular Therapeutics's last 12 months EBITDA is -$205M. |
| What is 4D Molecular Therapeutics's EBITDA margin? | 4D Molecular Therapeutics's last 12 months EBITDA margin is -12612%. |
| What is the current EV/EBITDA multiple of 4D Molecular Therapeutics? | Current EBITDA multiple of 4D Molecular Therapeutics is 0.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
